GO:0060044 negative regulation of cardiac muscle cell proliferation: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060044 describes any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle cell proliferation.
• It is a biological_process term that is central to the postnatal loss of cardiomyocyte renewal and to the heart's limited regenerative capacity.
• Key negative regulators include FoxO3, which suppresses cardiomyocyte proliferation by regulating Sfrp2 expression in postnatal mice.
• Dysregulation of this process contributes to pathologic myocardial hypertrophy, ischemia/reperfusion injury, and heart failure.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test causality of candidate negative regulators.
• The term is studied with proliferation assays, lineage tracing, transcriptomics, and functional rescue experiments in neonatal and adult hearts.
Description
GO:0060044, negative regulation of cardiac muscle cell proliferation, is a Gene Ontology biological_process term that captures the cellular programs which restrain the division of cardiac muscle cells. In the mammalian heart, cardiomyocytes exit the cell cycle shortly after birth, and this developmental switch is a major barrier to cardiac regeneration after injury. Understanding the molecular brakes that enforce this exit is therefore a central goal in cardiovascular biology and regenerative medicine. The term is defined as any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle cell proliferation, and it is supported by experimental evidence from mouse genetics, transcriptomics, and functional assays. Researchers study GO:0060044 to identify therapeutic targets that could safely re-engage cardiomyocyte proliferation without causing uncontrolled growth. Because the process is actively maintained in the postnatal heart, its regulators are attractive nodes for gene editing and cell-model discovery.
negative regulation of cardiac muscle cell proliferation At A Glance
| GO ID | GO:0060044 |
|---|---|
| GO term | negative regulation of cardiac muscle cell proliferation |
| Ontology | biological_process |
| Synonym | negative regulation of heart muscle cell proliferation |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle cell proliferation. |
| Major function | Restrains cardiomyocyte division and supports the postnatal post-mitotic state. |
| Related processes | Cardiac regeneration, cell-cycle exit, hypertrophy, and ischemia/reperfusion injury. |
| Key regulators | FoxO3, Sfrp2, Hmbox1, PCNA, POLD1, and metabolic/epigenetic modifiers. |
| Research relevance | Target discovery for cardiac regeneration and disease modeling. |
What Is GO:0060044?
In practical terms, GO:0060044 refers to any biological mechanism that decreases the rate or extent of cardiac muscle cell proliferation. This includes transcriptional repression of pro-proliferative genes, activation of cell-cycle inhibitors, secreted signals that block cardiomyocyte division, and metabolic or epigenetic changes that lock cardiomyocytes into a post-mitotic state. The term is not a single pathway but a collection of processes that converge on reduced cardiomyocyte proliferation.
Why Is negative regulation of cardiac muscle cell proliferation Important in Cell Biology?
GO:0060044 is important because the inability of adult cardiomyocytes to proliferate is a principal cause of irreversible heart damage after myocardial infarction and in heart failure. The pathways that enforce this negative regulation are also implicated in pathologic hypertrophy and ischemia/reperfusion injury, where altered proliferation and survival signaling determine clinical outcomes. By defining the molecular brakes on cardiomyocyte proliferation, this GO term provides a framework for identifying therapeutic targets that could promote regeneration or prevent maladaptive growth.
• Explains why the neonatal heart regenerates while the adult heart does not.
• Provides a mechanistic basis for cardiac regeneration therapies.
• Links cell-cycle exit to metabolic reprogramming in the postnatal heart.
• Connects negative regulation of proliferation to pathologic hypertrophy.
• Highlights survival and metabolic regulators such as Hmbox1 in ischemia/reperfusion injury.
• Supports discovery of secreted factors like Sfrp2 that modulate cardiomyocyte division.
• Guides CRISPR-based validation of candidate negative regulators.
• Informs disease models for heart failure, hypertrophy, and regenerative failure.
• Helps distinguish adaptive from maladaptive cardiac growth.
• Enables cross-species comparison of cardiomyocyte maturation and regeneration.
What Happens During negative regulation of cardiac muscle cell proliferation?
Transcriptional repression of pro-proliferative programs
In simple terms: The cell turns down genes that would normally drive division.
Negative regulation of cardiac muscle cell proliferation often begins with transcription factors that repress cell-cycle and developmental genes. FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice, providing a direct transcriptional mechanism for this GO term. This repression reduces the frequency of cardiomyocyte division and helps establish the post-mitotic state.
Secreted inhibitory signals
In simple terms: Cells release signals that tell neighboring heart muscle cells to stop dividing.
Secreted factors can act as paracrine brakes on cardiomyocyte proliferation. Sfrp2, regulated by FoxO3, is one such signal that modulates cardiomyocyte proliferation in the postnatal heart. Such secreted inhibitors coordinate tissue-level control of cardiac muscle cell division and are relevant to regeneration strategies.
Cell-cycle and DNA replication restraint
In simple terms: The machinery that copies DNA and divides cells is actively restrained.
Proteins involved in DNA replication and cell-cycle progression, such as PCNA and POLD1, are linked to pathologic myocardial hypertrophy when targeted, indicating that restraining their activity is part of negative regulation of cardiomyocyte proliferation. This connects the GO term to the molecular control of replication and hypertrophy.
Metabolic and epigenetic locking of the post-mitotic state
In simple terms: Changes in metabolism and gene packaging keep heart muscle cells from dividing.
Metabolic reprogramming and protein modifications, including lactylation, are associated with the neonatal heart's transition away from proliferation. These changes reinforce the post-mitotic state and contribute to the negative regulation captured by GO:0060044.
Survival and stress signaling integration
In simple terms: Stress pathways can either protect or further restrict heart muscle cell division.
Hmbox1 inhibition promotes cardiomyocyte survival and glucose metabolism through Gck activation in ischemia/reperfusion injury, showing that survival and metabolic signaling intersect with proliferation control. This integration is important for understanding how negative regulation of proliferation is maintained under stress.
Key Genes Involved in GO:0060044 negative regulation of cardiac muscle cell proliferation
The following genes and proteins have been experimentally linked to negative regulation of cardiac muscle cell proliferation or to closely related cardiac proliferation and regeneration processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FoxO3 | Transcription factor controlling cardiomyocyte proliferation and heart regeneration via Sfrp2 | Central regulator of postnatal cardiomyocyte cell-cycle exit |
| Sfrp2 | Secreted Wnt modulator downstream of FoxO3 that influences cardiomyocyte proliferation | Paracrine brake on cardiac muscle cell division |
| Hmbox1 | Inhibition promotes cardiomyocyte survival and glucose metabolism via Gck in ischemia/reperfusion injury | Links metabolic stress to cardiomyocyte survival and proliferation control |
| Gck | Glucose metabolism enzyme activated downstream of Hmbox1 inhibition | Metabolic node in cardiomyocyte survival and proliferation |
| PCNA | DNA replication clamp; targeting prevents pathologic myocardial hypertrophy | Replication-linked target in hypertrophy |
| POLD1 | DNA polymerase involved in replication; targeting prevents pathologic hypertrophy | Replication machinery in cardiac growth control |
| DUSP5 | Phosphatase that inhibits smooth muscle cell proliferation and suppresses pulmonary hypertension and right ventricular hypertrophy | Indirect relevance to cardiac proliferative control |
| Calcium/sarcomere components | Interplay between calcium and sarcomeres directs cardiomyocyte maturation during regeneration | Maturation-linked control of proliferation |
| Non-coding RNAs | Non-coding RNA therapeutics for cardiac regeneration | Regulatory layer affecting cardiomyocyte proliferation |
| Muscle satellite cell regulators | Satellite cell dysfunction in neuromuscular disorders | Context for muscle proliferation control |
| Lactylation-related proteins | Protein lactylation in cardiac metabolic reprogramming in neonatal mouse hearts | Epigenetic/metabolic control of postnatal proliferation |
| Cell-cycle inhibitors (general) | Restrain cardiomyocyte division in the postnatal heart | Candidate negative regulators for CRISPR validation |
| Wnt signaling components | Modulate cardiomyocyte proliferation via Sfrp2 | Pathway-level control of cardiac proliferation |
| Metabolic enzymes | Support or restrain cardiomyocyte proliferation through metabolic reprogramming | Targets for metabolic-proliferation studies |
| Stress-response kinases | Integrate survival and proliferation signals in ischemia/reperfusion | Therapeutic targets in cardiac injury |
| Sarcomeric proteins | Couple contractile maturation to proliferation arrest | Maturation-based models of proliferation control |
How Is negative regulation of cardiac muscle cell proliferation Regulated?
Negative regulation of cardiac muscle cell proliferation is controlled by a layered network of transcription factors, secreted signals, cell-cycle machinery, and metabolic-epigenetic modifiers. FoxO3 regulates Sfrp2 to control cardiomyocyte proliferation and heart regeneration in postnatal mice, establishing a transcriptional-secretory axis. Hmbox1 inhibition activates Gck and promotes cardiomyocyte survival and glucose metabolism during ischemia/reperfusion injury, linking metabolic stress to proliferation control. Targeting PCNA and POLD1 prevents pathologic myocardial hypertrophy, showing that replication machinery is a regulatory node. Protein lactylation is associated with cardiac metabolic reprogramming in neonatal hearts, providing an epigenetic layer that may reinforce the post-mitotic state. Non-coding RNAs also modulate cardiac regeneration and can act as additional regulators of this process.
negative regulation of cardiac muscle cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FoxO3 | Heart failure and impaired regeneration | Cardiomyocyte-specific knockout and overexpression in mice |
| Sfrp2 | Regenerative failure and altered cardiomyocyte proliferation | Secreted factor gain/loss-of-function in neonatal hearts |
| Hmbox1 | Ischemia/reperfusion injury and metabolic stress | Knockout or inhibition in cardiomyocytes |
| PCNA/POLD1 | Pathologic myocardial hypertrophy | Cardiomyocyte-targeted knockdown or knockout |
| DUSP5 | Pulmonary hypertension and right ventricular hypertrophy | Smooth muscle and cardiac conditional models |
Heart failure and regenerative failure
The inability of adult cardiomyocytes to proliferate contributes to irreversible loss of contractile tissue after injury, and negative regulation of cardiac muscle cell proliferation is a major barrier to regeneration. Strategies that transiently relieve this negative regulation are being explored for cardiac repair.
Pathologic myocardial hypertrophy
Targeting cardiomyocyte PCNA and POLD1 prevents pathologic myocardial hypertrophy, indicating that replication-related processes intersect with maladaptive cardiac growth. This links GO:0060044 to hypertrophy and heart failure progression.
Ischemia/reperfusion injury
Hmbox1 inhibition promotes cardiomyocyte survival and glucose metabolism through Gck activation in ischemia/reperfusion injury, showing that survival and metabolic pathways interact with proliferation control. This has implications for cardioprotection.
Pulmonary hypertension and right ventricular hypertrophy
DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy, illustrating how proliferative control in cardiovascular tissues affects cardiac disease.
From negative regulation of cardiac muscle cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is FoxO3 required for postnatal cardiomyocyte cell-cycle exit? | Cardiomyocyte-specific FoxO3 knockout mouse |
| Does Sfrp2 mediate FoxO3-dependent proliferation control? | Sfrp2 loss- and gain-of-function in neonatal cardiomyocytes |
| Can Hmbox1 inhibition protect against ischemia/reperfusion injury? | Hmbox1 knockout or pharmacological inhibition in mouse hearts |
| Do PCNA and POLD1 drive pathologic hypertrophy? | Cardiomyocyte-targeted PCNA/POLD1 knockdown or knockout |
| Does metabolic reprogramming reinforce the post-mitotic state? | Neonatal mouse heart lactylation and metabolic profiling |
| Can non-coding RNAs relieve negative regulation of proliferation? | Non-coding RNA therapeutics in cardiac regeneration models |
How to Study the negative regulation of cardiac muscle cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis and proliferation rate | Quantify cardiomyocyte proliferation |
| Ki67 staining | Cell-cycle entry | Assess proliferation in heart tissue |
| Lineage tracing | Origin and fate of proliferating cells | Track cardiomyocyte renewal |
| RNA-seq | Transcriptional changes | Identify negative regulators of proliferation |
| Non-coding RNA profiling | Regulatory RNA expression | Discover regeneration-associated RNAs |
| Lactylation profiling | Protein lactylation status | Link metabolism to proliferation control |
| Ischemia/reperfusion model | Cardiac injury and recovery | Test cardioprotective genes |
| Hypertrophy model | Pathologic cardiac growth | Evaluate PCNA/POLD1 targeting |
Proliferation and lineage-tracing assays
EdU/BrdU incorporation, Ki67 staining, and lineage tracing are used to quantify cardiomyocyte proliferation and to test whether candidate genes negatively regulate this process.
Transcriptomics and non-coding RNA profiling
RNA-seq and non-coding RNA profiling identify transcriptional programs and regulatory RNAs that enforce the post-mitotic state.
Metabolic and epigenetic profiling
Metabolic assays and lactylation profiling reveal how metabolic reprogramming contributes to negative regulation of cardiomyocyte proliferation in neonatal hearts.
Functional rescue in injury models
Ischemia/reperfusion and hypertrophy models combined with gene manipulation test whether relieving negative regulation improves cardiac outcomes.
How CRISPR Can Be Used to Study GO:0060044 negative regulation of cardiac muscle cell proliferation
Knockout
CRISPR knockout of candidate negative regulators such as FoxO3 or Sfrp2 in cardiomyocytes can test whether removing the brake increases proliferation and regeneration. Knockout of Hmbox1 can reveal its role in survival and metabolism during ischemia/reperfusion injury.
Point Mutation
Point mutations can dissect specific domains or phosphorylation sites in regulators like FoxO3 to determine which functions are required for negative regulation of proliferation. This approach helps separate proliferation control from other transcriptional activities.
Knock-in
Knock-in of reporters or tags allows precise tracking of negative regulators and their downstream targets in cardiac tissue. Tagged knock-in models can also enable biochemical isolation of complexes involved in this process.
Overexpression
Overexpression of negative regulators such as Sfrp2 or FoxO3 can test whether increasing their levels is sufficient to suppress cardiomyocyte proliferation. Overexpression of Hmbox1 or metabolic enzymes can probe survival and metabolic effects in injury models.
How EDITGENE Supports negative regulation of cardiac muscle cell proliferation Research
Researchers studying negative regulation of cardiac muscle cell proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining cardiomyocyte division or whether it is merely correlated with the post-mitotic state. Rigorous causal testing requires precise genome editing in relevant cardiac cell models, combined with functional proliferation and regeneration assays.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac muscle cell proliferation research.
Frequently Asked Questions About negative regulation of cardiac muscle cell proliferation
What is GO:0060044?
GO:0060044 is the Gene Ontology term for negative regulation of cardiac muscle cell proliferation, defined as any process that stops, prevents, or reduces the frequency, rate or extent of cardiac muscle cell proliferation.
What genes are involved in negative regulation of cardiac muscle cell proliferation?
Key genes include FoxO3, Sfrp2, Hmbox1, Gck, PCNA, and POLD1, based on experimental studies in cardiac models.
Why is negative regulation of cardiac muscle cell proliferation important?
It explains why adult cardiomyocytes do not regenerate after injury and is a barrier to cardiac repair therapies.
How is negative regulation of cardiac muscle cell proliferation studied?
Researchers use proliferation assays, lineage tracing, transcriptomics, metabolic profiling, and injury models to study this process.
What role does FoxO3 play in cardiomyocyte proliferation?
FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice.
How does Hmbox1 affect cardiomyocytes?
Inhibition of Hmbox1 promotes cardiomyocyte survival and glucose metabolism through Gck activation in ischemia/reperfusion injury.
Can CRISPR be used to study negative regulation of cardiac muscle cell proliferation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are used to test causal roles of candidate genes in this process.
What diseases are linked to negative regulation of cardiac muscle cell proliferation?
Heart failure, pathologic myocardial hypertrophy, ischemia/reperfusion injury, and right ventricular hypertrophy are linked to this process.
What is the synonym for GO:0060044?
The synonym is negative regulation of heart muscle cell proliferation.
How does metabolic reprogramming relate to cardiomyocyte proliferation?
Protein lactylation and metabolic changes in neonatal hearts are associated with the transition away from proliferation.
Conclusion
GO:0060044, negative regulation of cardiac muscle cell proliferation, defines the biological brakes that limit cardiomyocyte division and shape the heart's regenerative capacity. Experimental evidence implicates transcription factors, secreted signals, replication machinery, and metabolic-epigenetic modifiers in this process. Understanding these mechanisms is essential for developing safe strategies to promote cardiac repair or prevent pathologic growth. CRISPR-based models and functional assays provide the causal evidence needed to translate these insights into therapeutic targets.
References
- 1. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 2. Bei Y et al.. 2024. Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury.. Circulation 150(11):848-866 PMID: 38708602
- 3. Pal S et al.. 2025. Targeting Cardiomyocyte PCNA and POLD1 Prevents Pathologic Myocardial Hypertrophy.. Circ Res 137(9):1160-1181 PMID: 40948130
- 4. Xia JB et al.. 2025. FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice.. Nat Commun 16(1):2532 PMID: 40087279
- 5. Nguyen PD et al.. 2023. Interplay between calcium and sarcomeres directs cardiomyocyte maturation during regeneration.. Science 380(6646):758-764 PMID: 37200435
- 6. Braga L et al.. 2021. Non-coding RNA therapeutics for cardiac regeneration.. Cardiovasc Res 117(3):674-693 PMID: 32215566
- 7. Ferguson BS et al.. 2021. DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy.. Am J Physiol Heart Circ Physiol 321(2):H382-H389 PMID: 34142888
- 8. Zhang T et al.. 2024. The characterization of protein lactylation in relation to cardiac metabolic reprogramming in neonatal mouse hearts.. J Genet Genomics 51(7):735-748 PMID: 38479452
